Literature DB >> 29296809

In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy.

Seth J Rotz1, Nathan Luebbering1, Bradley P Dixon2, Eleni Gavriilaki3,4, Robert A Brodsky4, Christopher E Dandoy1, Sonata Jodele1, Stella M Davies1.   

Abstract

Transplantation-associated thrombotic microangiopathy is associated with complement activation in vitro.This data further supports the use of eculizumab for the treatment of patients with TA-TMA.

Entities:  

Year:  2017        PMID： 29296809      PMCID： PMC5728339          DOI： 10.1182/bloodadvances.2017008250

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  14 in total

Review 1.  Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Authors:  Benjamin L Laskin; Jens Goebel; Stella M Davies; Sonata Jodele
Journal:  Blood       Date:  2011-05-19       Impact factor: 22.113

2.  Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome.

Authors:  Arthur J Vaught; Eleni Gavriilaki; Nancy Hueppchen; Karin Blakemore; Xuan Yuan; Sara M Seifert; Sarah York; Robert A Brodsky
Journal:  Exp Hematol       Date:  2016-02-26       Impact factor: 3.084

3.  Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS).

Authors:  D C Morrison; L F Kline
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

Review 4.  New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Adam Nelson; Gregory Wallace; Benjamin L Laskin
Journal:  Transfus Apher Sci       Date:  2016-04-25       Impact factor: 1.764

5.  Modified Ham test for atypical hemolytic uremic syndrome.

Authors:  Eleni Gavriilaki; Xuan Yuan; Zhaohui Ye; Alexander J Ambinder; Satish P Shanbhag; Michael B Streiff; Thomas S Kickler; Alison R Moliterno; C John Sperati; Robert A Brodsky
Journal:  Blood       Date:  2015-04-10       Impact factor: 22.113

Review 6.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

Authors:  Sonata Jodele; Benjamin L Laskin; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Stella M Davies; Jens Goebel; Bradley P Dixon
Journal:  Blood Rev       Date:  2014-11-28       Impact factor: 8.250

7.  Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Authors:  Marina Noris; Miriam Galbusera; Sara Gastoldi; Paolo Macor; Federica Banterla; Elena Bresin; Claudio Tripodo; Serena Bettoni; Roberta Donadelli; Elisabetta Valoti; Francesco Tedesco; Alessandro Amore; Rosanna Coppo; Piero Ruggenenti; Eliana Gotti; Giuseppe Remuzzi
Journal:  Blood       Date:  2014-07-18       Impact factor: 22.113

8.  Complement activation via the alternative pathway by purified Salmonella lipopolysaccharide is affected by its structure but not its O-antigen length.

Authors:  N Grossman; L Leive
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

9.  Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults.

Authors:  Sonata Jodele; Stella M Davies; Adam Lane; Jane Khoury; Christopher Dandoy; Jens Goebel; Kasiani Myers; Michael Grimley; Jack Bleesing; Javier El-Bietar; Gregory Wallace; Ranjit S Chima; Zachary Paff; Benjamin L Laskin
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

10.  Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.

Authors:  Sonata Jodele; Tsuyoshi Fukuda; Kana Mizuno; Alexander A Vinks; Benjamin L Laskin; Jens Goebel; Bradley P Dixon; Ranjit S Chima; Russel Hirsch; Ashley Teusink; Danielle Lazear; Adam Lane; Kasiani C Myers; Christopher E Dandoy; Stella M Davies
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-09       Impact factor: 5.742
View more
  6 in total

Review 1.  Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.

Authors:  Samuel A Merrill; Robert A Brodsky
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Biomarkers for posttransplantation outcomes.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2018-04-05       Impact factor: 22.113

Review 3.  Clinical promise of next-generation complement therapeutics.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Rev Drug Discov       Date:  2019-07-19       Impact factor: 84.694

4.  New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT.

Authors:  Reem Elfeky; Giovanna Lucchini; Su-Han Lum; Giorgio Ottaviano; Natalia Builes; Zohreh Nademi; Alexandra Battersby; Terence Flood; Stephen Owens; Andrew J Cant; Helen Young; Sinéad Greener; Patrick Walsh; David Kavanagh; Srinivas Annavarapu; Kanchan Rao; Persis Amrolia; Robert Chiesa; Austen Worth; Claire Booth; Roderick Skinner; Bilyana Doncheva; Joseph Standing; Andrew R Gennery; Waseem Qasim; Mary Slatter; Paul Veys
Journal:  Blood Adv       Date:  2020-06-09

Review 5.  Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy.

Authors:  Eleni Gavriilaki; Vincent T Ho; Wilhelm Schwaeble; Thomas Dudler; Mohamed Daha; Teizo Fujita; Sonata Jodele
Journal:  Exp Hematol Oncol       Date:  2021-12-19

Review 6.  How I treat microangiopathic hemolytic anemia in patients with cancer.

Authors:  M R Thomas; M Scully
Journal:  Blood       Date:  2021-03-11       Impact factor: 22.113
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.